Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis (FP-CL2)

NCT00929578 Phase 2 COMPLETED Results posted

The objective of this study is to assess the safety and biologic activity of intralesional injection of fluphenazine in adult subjects with psoriasis.

Details

Lead sponsor	Tufts Medical Center
Phase	Phase 2
Status	COMPLETED
Enrolment	15
Start date	2008-11
Completion	2011-01

Conditions

• Psoriasis

Interventions

• Fluphenazine
• Placebo

Primary outcomes

• Change in Target Lesion Scoring Evaluated at Baseline and 4 Weeks — 4 weeks
  Actual change in target lesion score comparing 4 week score with baseline score. Improvement is positive, worsening is negative. Target lesions scores range from 0 (no disease) to 12 (severe disease), and are scored based on the sum of erythema (0-4), induration (0-4) and scale (0-4) scores.

Countries

United States